EUVIMEDEUVIMED entdecken
Crossref

Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC)

Luis E Raez, Kayla Brice, Katerine Dumais, Alejandro Lopez-Cohen, Delia Wietecha, Paola A Izquierdo, Edgardo S Santos, Hermán W Powery

Clinical Lung Cancer · 2023-03 · 24 (2) · 120-129

DOI: 10.1016/j.cllc.2022.11.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2023-03. Verfasst von Luis E Raez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Oncology Program, Memorial Cancer Institute/Florida Atlantic University, Pembroke Pines, FL. Electronic address: LRaez@mhs.net. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 108-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: European Society for Medical Oncology, International Association for the Study of Lung Cancer, American Society of Clinical Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the last decade, non-small-cell lung cancer (NSCLC) treatment has improved with the approval of multiple therapies to target specific genetic alterations. Though, next generation sequencing (NGS) has traditionally been conducted from tissue biopsy samples, developing data supports the use of plasma-based circulating tumor DNA (ctDNA), also known as "liquid biopsy," to complement tissue biopsy approaches in guiding front-line therapy. This study is a retrospective analysis of 170 new NSCLC patients treated at 2 cancer centers within a 5-year period who received both tissue and liquid biopsy NGS as standard of care. Based on a treatment schema defined by testing sufficiency, biomarker detection, and turnaround time (TAT), physicians based the majority of their treatments on liquid biopsy results (73.5%) versus tissue biopsy (25.9%). Liquid biopsy NGS returned results on average 26.8 days faster than tissue and reported higher testing success. For guideline-recommended biomarkers, liquid biopsy was 94.8% to 100% concordant with tissue. In comparing testing modalities, a liquid-first approach identified guideline-recommended biomarkers in 76.5% of patients versus 54.9% in a tissue-first approach. There was no significant difference in time-to-treatment, or survival outcomes (overall survival and progression free survival) based on liquid versus tissue biopsy findings. This research demonstrates that liquid biopsy NGS is an effective tool to capture actionable genetic alterations in NSCLC. Due to its high concordance to tissue, faster TAT, and similarity in outcomes and time-to-treatment, liquid biopsy can be used either as a first-line test or concordantly with tissue biopsy to guide treatment decisions in NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansRetrospective StudiesLiquid BiopsyBiopsyMutationBiomarkers, TumorHigh-Throughput Nucleotide Sequencing

Stichwörter der Autor:innen

Actionable genesLiquid biopsiesMolecular analysisNext generation sequencingTargeted therapies

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Thoracic Oncology Program, Memorial Cancer Institute/Florida Atlantic University, Pembroke Pines, FL. Electronic address: LRaez@mhs.net.
  • Memorial Cancer Institute, Pembroke Pines, FL.
  • Department of Medicine/Memorial Healthcare System, Pembroke Pines, FL.
  • Florida Precision Oncology/Genesis Care/Florida Atlantic University.

Förderung

  • European Society for Medical Oncology
  • International Association for the Study of Lung Cancer
  • American Society of Clinical Oncology
  • National Comprehensive Cancer Network

Zitieren

APA

Raez, L. E., Brice, K., Dumais, K., Lopez-Cohen, A., Wietecha, D., Izquierdo, P. A., Santos, E. S., & Powery, H. W. (2023). Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC). Clinical Lung Cancer, 24(2), 120-129. https://doi.org/10.1016/j.cllc.2022.11.007

Vancouver

Raez LE, Brice K, Dumais K, Lopez-Cohen A, Wietecha D, Izquierdo PA, et al. Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC). Clinical Lung Cancer. 2023;24(2):120-129. doi:10.1016/j.cllc.2022.11.007

BibTeX
@article{Raez2023,
  author = {Raez, Luis E and Brice, Kayla and Dumais, Katerine and Lopez-Cohen, Alejandro and Wietecha, Delia and Izquierdo, Paola A and Santos, Edgardo S and Powery, Hermán W},
  title = {Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC)},
  journal = {Clinical Lung Cancer},
  year = {2023},
  volume = {24},
  number = {2},
  pages = {120--129},
  doi = {10.1016/j.cllc.2022.11.007}
}
Kostenlos starten →